Differences in CD33 intensity between various myeloid neoplasms.
We measured the concentration of CD33 antigen on the surface of cells in 315 bone marrow (BM) samples and 114 corresponding peripheral blood (PB) samples from patients with various leukemias (acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], myeloproliferative disorder [MPD] other than CML, myelodysplastic syndrome [MDS]) and from control subjects. Overall CD33 intensity in total CD33+ cells was significantly higher in BM than in PB. CD33 intensity in total BM CD33+ cells differed significantly with the type of disease. The median number of CD33 molecules per cell was highest in AML, followed by MDS, CML, and control subjects and lowest in MPD. When only CD34+/CD33+ cells were examined, CD33 molecules per cell were highest in CD34+ cells in AML and lowest in MPD (P = .027). Patients with AML or MDS younger than 60 years had significantly higher intensity of CD33 expression on CD34+ cells than patients 60 years or older. Levels of CD33 intensity did not correlate with cytogenetics in patients with AML or MDS. There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias.
Jilani
Iman
I
Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Estey
Elihu
E
Huh
Yang
Y
Joe
Youngson
Y
Manshouri
Taghi
T
Yared
Marwan
M
Giles
Francis
F
Kantarjian
Hagop
H
Cortes
Jorge
J
Thomas
Deborah
D
Keating
Michael
M
Freireich
Emil
E
Albitar
Maher
M
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000032:analysis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000276:immunology* / Q000473:pathology; D005434:Flow Cytometry; D000079982:Gemtuzumab; D006801:Humans; D016130:Immunophenotyping; D000922:Immunotoxins; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000473:pathology; D011446:Prospective Studies; D015203:Reproducibility of Results; D063268:Sialic Acid Binding Ig-like Lectin 3; D016037:Single-Blind Method; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D000922:Immunotoxins; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab